SCHEMBL25530871

SCHEMBL25530871

CC(C)(C)c1ccc(C(C)(C)C)c(OC(F)(F)F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
KIF11 P52732 1/20 0.37
ALDH1A1 P00352 3/20 0.36
TRPV1 Q8NER1 2/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NR1I2 O75469 1/20 0.34
PDE2A O00408 1/20 0.34
EPHX2 P34913 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
RECQL P46063 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10064792 0.81 PDE2A (0.41) CA1CA2CA9KIF11ALDH1A1
SCHEMBL22254648 0.81 HTT (0.43) CA2ALDH1A1PDE2AKDM4EACHE
SCHEMBL15803005 0.81 KDM4E (0.40) CA1CA2CA9KIF11ALDH1A1
SCHEMBL28857734 0.79 CA1 (0.44) CA1CA2CA9KIF11ALDH1A1
SCHEMBL12828080 0.79 CA1 (0.42) CA1CA2CA9ALDH1A1TRPV1
SCHEMBL13698781 0.79 CA1 (0.42) CA1CA2CA9ALDH1A1TRPV1
SCHEMBL10064802 0.79 NOTUM (0.41) CA1CA2CA9KIF11ALDH1A1
SCHEMBL13091406 0.79 CNR2 (0.43) ALDH1A1TDP1MEN1GAAKMT2A
SCHEMBL21670003 0.79 GAA (0.38) KIF11ALDH1A1HPGDPDE2ANR1H4
SCHEMBL22379883 0.79 ALDH1A1 (0.47) CA1CA2KIF11ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230167099-A1 NEW PYRAZINE COMPOUND Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-06-01 US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 CA1 4817/4885CA2 3774/4885CA9 2577/4885
US-20230167099-A1 NEW PYRAZINE COMPOUND EGFR, ERBB2, WEE1 CA1 2691/4885CA2 1820/4885CA9 2604/4885
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 CA1 4525/4885CA2 2151/4885CA9 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.